| abstract |
Human 11cb splice variant polypeptides and DNA (RNA) encoding such an 11cbnsplice variant and a procedure for producing such polypeptides by recombinant techniquesnare disclosed. Also disclosed are methods for utilizing such an 11cb splice variant for thentreatment of infections, such as bacterial, fungal, protozoan and viral infections, particularlyninfection caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson'sndisease; both acute and congestive heart failure; hypotension; hypertension; urinarynretention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benignnprostatic hypertrophy and psychotic and neurological disorders, including anxiety,nschizophrenia, manic depression, delirium, dementia or severe mental retardation;ndyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others.nAntagonists against such an 11cb splice variant and their use as a therapeutic to treatninfections, such as bacterial, fungal, protozoan and viral infections, particularly infactionncaused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease;nboth acute and congestive heart failure; hypotension; hypertension; urinary retention;nosteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostaticnhypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia,nmanic depression, delirium, dementia or severe mental retardation; and dyskinesias, such asnHuntington's disease or Gilles dela Tourett's syndrome, among others, are also disclosed.nAlso disclosed are diagnostic assays for detecting diseases related to mutations in thennucleic acid sequences and altered concentrations of the polypeptides. Also disclosed arendiagnostic assays for detecting mutations in the polynucleotides encoding the 11cb splicenvariant and for detecting altered levels of the polypeptide in a host. |